ArticleNeuro-oncology advances
Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Temporal Dynamics and Heterogeneity in Brain Metastases: A Single-Center Retrospective Analysis of Vulnerabilities in Current MRI Surveillance Practices.Medicina (Kaunas, Lithuania) · 2026Observational
- Continuous multimodal data supply chain and expandable clinical decision support for oncology.NPJ digital medicine · 2025Article
- Artificial intelligence in the task of segmentation and classification of brain metastases images: current challenges and future opportunities.Frontiers in neurology · 2025Review
- Article
- Clinical, Cultural, Computational, and Regulatory Considerations to Deploy AI in Radiology: Perspectives of RSNA and MICCAI Experts.Radiology. Artificial intelligence · 2024Article
- A large open access dataset of brain metastasis 3D segmentations on MRI with clinical and imaging information.Scientific data · 2024Article
- Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline.Journal of neuro-oncology · 2024Article
- Introduction to the Special Issue on "Role of Novel Imaging Technique in Brain Tumors".Cancers · 2024Article
- Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas.Scientific reports · 2023Article
- A multi-institutional pediatric dataset of clinical radiology MRIs by the Children's Brain Tumor Network.ArXiv · 2023Article
- Article
- Automatically tracking brain metastases after stereotactic radiosurgery.Physics and imaging in radiation oncology · 2023Article
- Artificial-intelligence-driven measurements of brain metastases' response to SRS compare favorably with current manual standards of assessment.Neuro-oncology advancesArticle
- Automatic longitudinal assessment of brain metastases improves detection of disease progression.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment of brain metastases can be tailored to individual lesions with treatments such as stereotactic radiosurgery. Accurate surveillance of lesions is a prerequisite but challenging in patients with multiple lesions and prior imaging studies, in a process that is laborious and time consuming. We aimed to longitudinally track several lesions using a PACS-integrated lesion tracking tool (LTT) to evaluate the efficiency of a PACS-integrated lesion tracking workflow, and characterize the prevalence of heterogenous response (HeR) to treatment after Gamma Knife (GK). Methods: We selected a group of brain metastases patients treated with GK at our institution. We used a PACS-integrated LTT to track the treatment response of each lesion after first GK intervention to maximally seven diagnostic follow-up scans. We evaluated the efficiency of this tool by comparing the number of clicks necessary to complete this task with and without the tool and examined the prevalence of HeR in treatment. Results: A cohort of eighty patients was selected and 494 lesions were measured and tracked longitudinally for a mean follow-up time of 374 days after first GK. Use of LTT significantly decreased number of necessary clicks. 81.7% of patients had HeR to treatment at the end of follow-up. The prevalence increased with increasing number of lesions. Conclusions: Lesions in a single patient often differ in their response to treatment, highlighting the importance of individual lesion size assessments for further treatment planning. PACS-integrated lesion tracking enables efficient lesion surveillance workflow and specific and objective result reports to treating clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.